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Key message 
This phase II study evaluated the response rate of copanlisib in patients with indolent or 
aggressive malignant lymphoma. Results indicated that copanlisib induced clinically 
meaningful responses in this heavily pretreated population. Serious adverse events linked to 
PI3K-δ inhibitors, such as increased liver transaminitis, GI toxicity and opportunistic 
infection, were infrequent with copanlisib.  
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Abstract 
Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with 
predominant activity against the α- and δ- isoforms. 
Patients and methods: This phase II study evaluated the response rate of copanlisib 
administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or 
aggressive malignant lymphoma.  Archival tumor tissues were used for 
immunohistochemistry, gene-expression profiling, and mutation analysis. 
Results: Thirty-three patients with indolent lymphoma and 51 with aggressive lymphoma 
received copanlisib.  Follicular lymphoma (48.5%) and peripheral T-cell lymphoma (33.3%) 
were the most common histologic subtypes.  Most patients (78.6%) had received prior 
rituximab and 54.8% were rituximab-refractory.  Median duration of treatment was 23 weeks 
and 8 weeks in the indolent and aggressive cohorts, respectively (overall range, 2–138).  
Eighty patients were evaluated for efficacy.  The objective response rate was 43.7% (14/32) 
in the indolent cohort and 27.1% (13/48) in the aggressive cohort; median progression-free 
survival was 294 days (range, 0–874) and 70 days (range, 0–897), respectively; median 
duration of response was 390 days (range, 0–825) and 166 days (range, 0–786), respectively.  
Common adverse events included hyperglycemia (57.1%; grade ≥3, 23.8%), hypertension 
(54.8%; grade ≥3, 40.5%), and diarrhea (40.5%; grade ≥3, 4.8%), all generally manageable.  
Neutropenia occurred in 28.6% of patients (grade 4, 11.9%).  Molecular analyses showed 
enhanced antitumor activity in tumors with upregulated PI3K pathway gene expression. 
Conclusion: Intravenous copanlisib demonstrated promising efficacy and manageable 
toxicity in heavily pretreated patients with various subtypes of indolent and aggressive 
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malignant lymphoma.  Subtype-specific studies of copanlisib in patients with follicular, 
peripheral T-cell, and mantle cell lymphomas are ongoing. 
This trial is registered with ClinicalTrials.gov number NCT01660451 (Part A). 
Key words: copanlisib, treatment, malignant lymphoma, PI3K inhibitor  
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Introduction 
Non-Hodgkin’s lymphoma comprises a heterogeneous group of malignant lymphomas, with 
both indolent and aggressive subtypes [1].  The B-cell receptor (BCR) signaling pathway is 
critical for the development, proliferation, and survival of malignant B-cells.  Drugs targeting 
BCR pathway kinases, including the Bruton’s tyrosine kinase inhibitor ibrutinib [2] and the 
phosphatidylinositol 3-kinase (PI3K)-δ isoform inhibitor idelalisib [3], have proven to be 
effective treatment options in patients who have relapsed or are refractory to standard 
therapy. 
However, fatal and/or serious toxicities have been associated with idelalisib use [3, 4] and, 
recently, frequent serious adverse events, including hepatic and gastrointestinal toxicity, 
colitis, opportunistic infections, autoimmune toxicities, and pneumonitis, have raised safety 
concerns around idelalisib in combination with standard therapies [5–7].  Therefore, new 
approaches, such as dual inhibition of PI3K-δ and PI3K-α and/or combination with a 
Bruton’s tyrosine kinase inhibitor, are necessary to both mitigate toxicity issues and improve 
efficacy [8–10]. 
Copanlisib (BAY 80-6946; Bayer AG, Berlin, Germany) is an intravenous pan-class I PI3K 
inhibitor with predominant activity against the PI3K-α and PI3K-δ isoforms [11].  A first-in-
human phase I study established the maximum tolerated dose of copanlisib as 0.8 mg/kg 
administered on days 1, 8, and 15 of a 28-day cycle [12].  In an expansion cohort including 
non-Hodgkin’s lymphoma patients, severe toxicities were low and there were early signs of 
efficacy, including complete response (CR) or partial response (PR) in all six patients with 
relapsed or refractory follicular lymphoma (FL), and one of three patients with diffuse large 
B-cell lymphoma (DLBCL) [12]. 
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This open-label, uncontrolled, phase II study evaluated the efficacy and safety of intravenous 
copanlisib administered intermittently in heavily pretreated patients with relapsed or 
refractory, indolent or aggressive malignant lymphoma (ClinicalTrials.gov identifier: 
NCT01660451; Part A).  Biomarker analyses were performed to identify a possible gene 
signature profile that may associate with response. 
Patients and methods 
Study design and patient eligibility 
The study population comprised two cohorts of 30 patients each with either indolent 
lymphoma or chronic lymphocytic leukemia (CLL), or aggressive malignant lymphoma, 
relapsed or refractory to two or more prior lines of therapy.  Following early signs of clinical 
activity, the protocol was amended to enroll additional patients with aggressive lymphoma 
(mantle cell lymphoma [MCL] and T-cell lymphoma).  Separate extension studies for 
relapsed or refractory, indolent lymphoma (NCT01660451, Part B) and DLBCL 
(NCT02391116) are ongoing.  The study protocol and amendments were approved by all 
relevant institutional review boards and ethics committees.  All patients gave written, 
informed consent. 
The primary efficacy variable was objective response rate (ORR), defined as the proportion 
of patients who achieved a CR, an unconfirmed CR (uCR), or a PR [13], or CR or PR for 
patients with CLL [14].  The database cut-off date was November 4, 2013 for the primary 
analysis set, and October 1, 2015 including expansion patients.  Secondary variables included 
progression-free survival, overall survival, and duration of response.  Additional variables 
included time to response, lesion size, biomarkers, and safety. 
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The indolent cohort consisted of histologically confirmed grade 1, 2, or 3a FL, marginal zone 
lymphoma, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, or CLL.  
Aggressive lymphomas included histologically confirmed grade 3b FL, transformed indolent 
lymphoma, DLBCL, mediastinal large B-cell lymphoma, MCL, unspecified peripheral T-cell 
lymphoma (PTCL), anaplastic large-cell lymphoma primary systemic type, or angio-
immunoblastic T-cell lymphoma.  Additional inclusion criteria and exclusion criteria are 
described in the Supplementary Materials, available at Annals of Oncology online. 
Eligible patients received 0.8 mg/kg copanlisib intravenously over a 1-hour infusion on 
days 1, 8, and 15 of a 28-day cycle until disease progression, worsening of Eastern 
Cooperative Oncology Group performance status of ≥3, or unacceptable toxicity.  Details of 
plasma glucose requirements pre-infusion, management of post-infusion hyperglycemia, and 
permitted dose reductions are described in the Supplementary Materials. 
Dose reductions to 0.6 mg/kg and 0.4 mg/kg were permitted if clinically significant toxicities 
were observed; re-escalation was not permitted.  Treatment was discontinued if the 0.4 mg/kg 
dose was not tolerated. 
Assessments 
Tumor assessments were performed at screening and every two cycles thereafter during year 
1, every three cycles during year 2, and every six cycles during year 3.  Radiologic evaluation 
of efficacy was performed by central blinded independent review; in patients with CLL, 
treatment response was determined by investigator assessment.  Patients were followed off-
study for overall survival at 3-month intervals for up to 3 years.  Safety was evaluated 
according to National Cancer Institute Common Terminology Criteria for Adverse Events 
version 4.0.  Measurements of glycated hemoglobin, plasma glucose, and blood pressure are 
described in the Supplementary Materials.  Archival formalin-fixed paraffin-embedded tumor 
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tissues were evaluated for biomarkers, for which detailed methods are described in the 
Supplementary Materials. 
Statistical methods 
Pre-specified primary evaluation was to reject the null hypothesis of a true ORR of ≤5% in 
the indolent or aggressive lymphoma cohorts, separately.  ORR was evaluated using a one-
sided exact binomial test (significance level of 5%) and was designed to have 95% power per 
cohort, if the true ORR was 30%, resulting in a requirement of 30 evaluable patients per 
cohort.  Exact binomial Clopper-Pearson confidence intervals (CI) with confidence level of 
90% were provided for ORR.  Time-to-event variables were analyzed using Kaplan-Meier 
methodology.  In order to study promising lymphoma histologies in more detail, the 
aggressive cohort was expanded with an additional 17 patients, beyond those recruited for the 
primary evaluation.  Data from these patients were included in a descriptive analysis of the 
study.  Detailed methods are described in the Supplementary Materials. 
Results 
Patients 
Eighty-four patients received copanlisib: 33 in the indolent cohort and 34 in the aggressive 
cohort for the primary analysis, and 17 additional patients with aggressive lymphoma (four 
patients with MCL and 13 with PTCL) enrolled into an expansion cohort (supplementary 
Figure S1).  The majority had advanced-stage disease at study entry (Ann Arbor stage III/IV, 
73.7% indolent, 88.2% aggressive) (Table 1). 
Patients had received a median of three lines of systemic anticancer therapy, and the majority 
had received chemotherapy with or without immunotherapy or immunotherapy monotherapy 
(supplementary Table S1).  Twenty-three patients (69.7%) in the indolent cohort were 
10 
refractory to one or more regimens with rituximab and 15 (45.5%) were refractory to one or 
more regimens with bendamustine. 
Copanlisib treatment 
Median treatment duration was 13.9 weeks overall (range, 2.0–137.9): 22.7 weeks 
(5.7 cycles) in the indolent cohort and 8.0 weeks (2.0 cycles) in the aggressive cohort.  
Patients with indolent or aggressive lymphoma received a median number of 15 (range, 1–
101) and six (range, 1–95) copanlisib infusions, respectively; patients received a median of 
90.5% of the planned dose overall.  Fifty patients (59.5%) had dose interruptions or delays 
because of adverse events, and 11 (13.1%) had dose reduction because of adverse events 
(Supplementary Results); interruptions or delays had a median duration of 1 week (range, 
0.1–1.7). 
Efficacy 
Sixty-six patients were included in the per protocol analysis set for the primary efficacy 
analysis.  The ORR was 43.8% (90% CI 28.7–59.7) in the indolent cohort and 29.4% (90% 
CI 16.9–44.8) in the aggressive cohort, statistically confirming the hypothesis of an ORR 
>5% (P<0.0001 in each cohort) (Table 2).  A waterfall plot of best change in target lesion 
size from baseline per investigator assessment indicated that 66.7% of patients (20/30) in the 
indolent cohort (Figure 1A) and 42.5% (17/40) in the aggressive cohort (Figure 1B) had 
≥50% reduction in lesion size. 
CRs/uCRs were observed in three of 15 FL patients (20.0%) and PRs in a further three 
patients (20.0%); the ORR was 40% (supplementary Table S2).  PRs were observed in five of 
13 patients with CLL (ORR 38.5%), two of three patients with marginal zone lymphoma 
(ORR 66.7%), and one patient with small lymphocytic lymphoma (ORR 100%).  In the initial 
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set of patients with aggressive lymphoma, five of seven with MCL and two of four with 
PTCL had CR/uCR or PR, prompting additional enrollment, expanding the response analysis 
to 48 patients.  The ORR for the aggressive lymphoma expansion cohort was 27.1% (90% CI 
16.8–39.6).  Objective responses were achieved in patients with DLBCL (one PR; ORR 
6.7%), PTCL (two CRs, one PR; ORR 21.4%), MCL (two uCRs, five PRs; ORR 63.6%), and 
transformed FL (both PRs; ORR 33.3%) (supplementary Table S2). 
Median time to response was 52 days (range, 0–109) in the indolent cohort and 51 days 
(range, 0–117) in the aggressive cohort, and was generally observed at the first response 
assessment (supplementary Figure S2).  Median progression-free survival was 294 days 
(range, 0–874) in the indolent cohort and 70 days (range, 0–897) in the aggressive cohort 
(Figure 2A).  At 12 months, progression-free survival was 45% and 13% in the indolent and 
aggressive cohorts, respectively.  The median duration of response was 390 days (range, 0–
825) and 166 days (range, 0–786 days) in the indolent and aggressive cohorts, respectively 
(Figure 2B).  Median overall survival was 657 days in the indolent cohort (range, 0–958) and 
183 days in the aggressive cohort (range, 0–1017) (Figure 2C).  At 12 months, overall 
survival was 69% and 42% in patients with indolent and aggressive lymphoma, respectively. 
Biomarkers 
Loss of or low tumor PTEN protein expression was detected in six of 16 patients in the 
indolent cohort (including 2/10 with FL) and four of 26 patients in the aggressive cohort 
(supplementary Table S3).  High expression of PI3K and/or BCR pathway genes occurred in 
nine of 15 patients in the indolent cohort (including 4/10 with FL) and seven of nine patients 
in the aggressive cohort. 
In the indolent cohort, 13 of 18 patients (including 6/11 with FL) had upregulated PI3K 
pathway gene expression (supplementary Table S3).  Upregulation of PI3K pathway gene 
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expression was observed in 10 of 11 patients with either a CR or a PR, or ≥50% best decrease 
in target lesion size from baseline, but only three of seven patients with <50% best decrease 
in target lesion size (Figure 1A).  In the aggressive cohort, nine of 26 patients had 
upregulation of PI3K pathway gene expression (supplementary Table S3), including three of 
seven patients with ≥50% best reduction in target lesion size (of whom two had CR/uCR) and 
six of 13 patients with <50% best decrease in target lesion size (Figure 1B). 
Results from DNA next-generation sequencing are described in the Supplementary Materials.  
An unfavorable tumor microenvironment gene signature was more frequently expressed in 
patients with indolent or aggressive lymphoma who were less responsive to copanlisib, with 
<50% best decrease in target lesion size (Figures 1A and 1B). 
Safety 
Treatment-emergent adverse events (TEAEs) are shown in Table 3.  Drug-related TEAEs are 
shown in supplementary Table S4.  The most common TEAEs were hyperglycemia (59.5%), 
hypertension (54.8%), fatigue (48.8%), and diarrhea (40.5%).  In most cases, grade 3 was the 
worst grade of TEAE (overall 60.7%; 51/84).  Serious grade 3, 4, and 5 TEAEs were reported 
in 31.0% (26/84), 4.8% (4/84), and 11.9% (10/84) of patients, respectively.  Serious grade 3 
or 4 TEAEs occurring in two or more patients included: grade 3 lung infection (10.7%; 9/84); 
grade 3 diarrhea and grade 3 febrile neutropenia (3.6% each; 3/84); and grade 4 decreased 
neutrophil count, grade 3 hyperglycemia, grade 3 pneumonitis (one infectious and one 
possibly infectious), grade 3 pancreatitis, grade 3 cardiac disorders - other, and grade 3 
infection/infestations - other (2.4% each; 2/84).  There was one case of serious grade 3 
hypertension and one case of serious grade 3 acute coronary syndrome.  Serious drug-related 
TEAEs were recorded in 32.1% of patients (supplementary Table S5). 
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There were 10 deaths (Table 3), four of which were considered possibly drug-related 
(supplementary Table S5), including one case of meningitis caused by opportunistic infection 
with Cryptococcus neoformans in a patient with CLL occurring 8 days after one infusion of 
copanlisib. 
Hyperglycemic and hypertension events were all grade ≤3 and transitory (supplementary 
Table S6).  Seventeen patients received insulin to manage post-infusion hyperglycemia 
(grade 2, 35.3% [6/17]; grade 3, 64.7% [11/17]), of whom nine had blood glucose 
≤160 mg/dL.  Increases in mean glycated hemoglobin from baseline to end of treatment were 
<0.5% in both indolent and aggressive cohorts (supplementary Table S6).  Seventeen patients 
received post-dose antihypertensive treatment for grade 3 hypertension. 
All-grade hematologic toxicities included decreased neutrophil count (34.5%; grade 3/4, 
29.8%), anemia (28.6%; grade 3/4, 14.3%), and decreased platelet count (17.9%; grade 3/4, 
11.9%), and infections and infestations were reported in 64.3% of patients (grade 1/2, 39.3%; 
drug-related all-grade, 29.8%).  Infections of grade ≥3 occurring in two or more patients 
included lung infection (14.3%; 12/84) and skin infection, urinary tract infection, and other 
(2.4% each; 2/84).  There were three reports of pneumonitis overall, including one grade 3 
opportunistic infection with Pneumocystis jirovecii and one grade 1 non-infectious event.  
Diarrhea was mostly mild (grade 1, 22.6%; grade 2, 13.1%; grade ≥3, 4.8%) and was 
manageable with a standard symptomatic treatment such as loperamide.  There were no 
reported cases of colitis or intestinal perforation. 
TEAEs leading to permanent treatment discontinuation were reported in 25.0% of patients 
(Table 3).  No patient discontinued because of hyperglycemia or hypertension.  
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Discussion 
In this exploratory phase II study in heavily pretreated patients with relapsed or refractory, 
indolent or aggressive lymphoma, or CLL, copanlisib monotherapy was shown to be 
effective, confirming the early signal of activity reported in a lymphoma expansion cohort in 
the phase I study [12].  The ORR was 43.8% in the indolent cohort (CR/uCR 9.4%) and 
27.1% in the aggressive cohort (CR/uCR 8.3%).  A median duration of response of 
12.8 months and median progression-free survival of 9.7 months were seen in the indolent 
cohort.  The two largest subtypes of patients in the indolent cohort (FL and CLL) had ORRs 
of 40% (CR/uCR) and 38.5%, respectively.  These results in the indolent cohort are similar to 
or slightly lower than the ORR and progression-free survival results reported by Flinn et al 
[15] and Gopal et al [16] with idelalisib in similar patient populations, although lower than 
those reported by Byrd et al [17] for ibrutinib in patients with CLL and small lymphocytic 
lymphoma.  Such cross-study comparisons are inconclusive due to the small numbers of 
patients, although the CR/uCR rate of 20% seen here in FL, as well as two CRs from six FL 
patients in the phase I study [12], are promising.  A larger study in patients with indolent 
lymphoma is ongoing (NCT01660451, Part B). 
In the aggressive cohort, the ORR ranged from 6.7% in DLBCL patients to 63.6% in MCL 
patients.  Responses to ibrutinib have been reported to be higher in patients with activated B-
cell (ABC) DLBCL compared with germinal center B-cell-like differentiation (GCB) 
DLBCL [18], but such subtyping of DLBCL was not available here.  Based on expression of 
PI3K-α and PI3K-δ in DLBCL lymphoma tissues, together with heightened activity of 
copanlisib compared with selective PI3K-δ or PI3K-α inhibition in ABC DLBCL models [9, 
10], exploration of copanlisib activity in ABC or GCB subtypes of DLBCL is ongoing 
(NCT02391116), and a rationale for combination with ibrutinib has been proposed [9, 10].  
15 
Objective responses have not been reported in studies with DLBCL patients treated with 
idelalisib. 
The ORR of 63.6% (including two uCRs) in MCL patients was favorable compared with 
reports of idelalisib (ORR 40%) [19] or ibrutinib (ORR 67%) [20].  Copanlisib activity in 
MCL is consistent with expression of PI3K-α and PI3K-δ, with increased PI3K-α expression 
in later-stage disease [8].  In PTCL patients, the ORR was 21.4% and included two CRs, 
which was similar to that seen in a phase I study in PTCL patients with the PI3K-δ,γ inhibitor 
duvelisib [21].  Therefore, further study with copanlisib in relapsed or refractory MCL and 
PTCL may be warranted. 
The safety profiles for PI3K inhibitors warrant careful scrutiny following the recent safety 
concerns for the oral agent idelalisib [5–7].  Hyperglycemia and hypertension were the most 
common TEAEs seen with copanlisib, were consistent with its target profile and route of 
administration, and were predicted [12].  Both were transient and manageable, and followed a 
similar pattern as previously reported [12], with blood pressure peaking 1–2 hours after the 
start of infusion and plasma glucose levels peaking 5–8 hours after the start of infusion, 
followed by a decline to baseline levels.  No patients discontinued because of either adverse 
event.  No hyperglycemic or hypertension events of grade ≥4 were reported, and serious 
events of grade 3 were reported in two patients and one patient, respectively, who all had 
baseline risk factors requiring planned hospitalization to adjust dosing.  Cardiac events were 
infrequent and low, and glycated hemoglobin levels did not increase compared with baseline. 
Infections are common for patients with hematologic malignancies such as CLL, and drugs 
inhibiting PI3K-δ or Bruton’s tyrosine kinase may exacerbate the rate and severity of 
infection [7, 22].  Copanlisib treatment decreased neutrophil count in 34.5% of patients 
(29.8% grade ≥3), yet serious febrile neutropenia was infrequent (three patients), as were 
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opportunistic infections (two patients) and pneumonitis (three patients).  Higher rates of 
pneumonitis have been reported with idelalisib in patients with relapsed lymphoma (11% 
[grade ≥3, 7%]; and 12.5% [grade ≥3, 10%]) [16, 19].  Similarly, the incidence of 
pneumonitis here was low (3.6%; one grade 1 non-infectious, one grade 3 infectious, one 
grade 3 possibly infectious). 
High rates of hepatic and gastrointestinal toxicity have been seen with idelalisib [22].  With 
idelalisib trials, the incidence of elevated aminotransferases ranged from 48% to 60% (all 
grade), with grade ≥3 8–13% in phase II [15, 16, 19].  Here, elevated alanine 
aminotransferase and aspartate aminotransferase were incidental findings in 25.6% of 
patients, almost all of which were grade 1 (23.2% and 24.4%, respectively; grade 3, 3.7% and 
2.4%, respectively).  Diarrhea was the most common adverse event reported in a phase II 
study of idelalisib (all-grade, 43%; grade ≥3, 13%) [15, 16, 19].  Late-onset idelalisib-
induced diarrhea has been reported, a possible symptom of autoimmune colitis [23].  In one 
study, 86% of patients (12/14) treated with idelalisib for ≥3 months with idelalisib-induced 
diarrhea had colitis with intra-epithelial lymphocytosis, crypt cell apoptosis, and neutrophilic 
infiltration of crypt epithelium [24].  Here, diarrhea was reported in 40.5% of patients 
(grade ≥3, 4.8%) and there were no reports of colitis.  Only one case of colitis was reported 
with copanlisib in the phase I study [12].  This differentiation may reflect the intermittent 
administration of intravenous copanlisib versus oral agents dosed continuously. 
Tumor gene expression and mutation analyses showed that consistent with the known low 
prevalence of PIK3CA mutations in lymphoma [25, 26], no mutations in PIK3CA, PIK3CB, 
PIK3CD, or PIK3CG, or PTEN, were detected.  Upregulation of PI3K pathway gene 
expression was frequently observed in indolent and aggressive lymphoma types.  Analysis of 
gene-expression data using response rate and progression-free survival (data not shown) as 
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clinical outcomes demonstrated increased copanlisib antitumor activity in cases with 
activated PI3K/BCR signaling, which, together with low expression of unfavorable tumor 
microenvironment genes, is consistent with the proposed mechanism of action of copanlisib.  
These preliminary results are therefore currently under further evaluation in an extension 
cohort of patients with FL. 
Overall, our data suggest that intravenous copanlisib may provide an effective therapeutic 
option for patients with relapsed or refractory, indolent or aggressive lymphoma whose 
disease has progressed after standard therapy.  Moreover, the safety profile of intravenous 
intermittently dosed copanlisib is distinct and manageable, and potentially advantageous, 
with a lower incidence of fatal and/or severe hepatic and gastrointestinal toxicity compared 
with oral PI3K inhibitors.  An extension study of copanlisib in patients with FL is ongoing, 
along with studies of copanlisib as monotherapy and in combination with standard 
chemotherapy in patients with indolent lymphoma (NCT02369016, NCT02367040, and 
NCT02626455) and aggressive lymphoma (NCT02391116).  
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Figure legends 
Figure 1.  Percent best change in target lesion size from baseline (investigator assessment) in 
the indolent (A) and aggressive (B) cohorts with corresponding status of baseline 
upregulation of PI3K/PTEN pathway gene expression and tumor microenvironment (full 
analysis set).  *NOTCH1 mutation by next-generation sequencing.  
a
Unfavorable tumor 
microenvironment gene-expression signature was defined as high (greater than the median 
value) weighted gene-expression scores combining genes expressed in stromal, 
inflammatory, and immune response pathways.  
b
Upregulation of PI3K/PTEN pathway gene 
expression was defined as PTEN protein loss (0% of tumor cells stained positive for PTEN 
by IHC) or low PTEN protein expression (1–4% of tumor cells stained positive), and/or a 
high PI3K/BCR gene-expression signature (defined by a weighted gene-expression score 
greater than the median value).  
c
Positive PTEN protein expression was defined as ≥5% of 
cells staining positive for PTEN by IHC.  
d
Includes peripheral T-cell lymphoma, peripheral 
T-cell lymphoma not otherwise specified, and angio-immunoblastic T-cell lymphoma.  
BCR – B-cell receptor; CR – complete response; GEA – gene-expression analysis; IHC –
 immunohistochemistry; PD – progressive disease; PR – partial response; SD – stable 
disease; uCR – unconfirmed complete response. 
Figure 2.  Progression-free survival (full analysis set) (A), duration of response (per protocol 
set) (B), and overall survival (full analysis set) (C) in patients in the indolent or aggressive 
cohorts receiving copanlisib. 
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Table 1.  Baseline demographics and disease characteristics 
Primary analysis set   
Indolent cohort 
(n=33) 
Aggressive cohort 
(n=34) 
Aggressive cohort, all 
(n=51) 
Total 
(N=84) 
Sex, n (%)     
Male 15 (45.5) 17 (50.0) 29 (56.9) 44 (52.4) 
Female 18 (54.5) 17 (50.0) 22 (43.1) 40 (47.6) 
Median age, years (range) 68.0 (46–89) 68.0 (22–90) 63.0 (22–90) 66.5 (22–90) 
Median time from initial diagnosis to start of study 
treatment, months (range) 
119.8 (20–244) 29.7 (6–212) 24.0 (6–281) 47.6 (6–281) 
Median time since first progression, months (range) 68.5 (10–177) 11.5 (0–100) 11.2 (0–100) 19.7 (0–177) 
Median time since most recent progression to start of 
study treatment, months (range) 
5.1 (1–31) 3.9 (0–18) 4.1 (0–21) 4.1 (0–31) 
Most recent histology of tumor, n (%)     
Indolent lymphoma or CLL 33 (100) 0 0 33 (39.3) 
CLL 13 (39.4) 0 0 13 (15.5) 
FL 16 (48.5) 0 0 16 (19.0) 
Grade 1, 2, or 3aa,b 15 (93.8) 0 0 15 (17.9) 
MZL 3 (9.1) 0 0 3 (3.6) 
50
51
52
53
54
55
56
57
58
59
60
2 
SLL 1 (3.0) 0 0 1 (1.2) 
Aggressive lymphoma 0 34 (100) 51 (100) 51 (60.7) 
DLBCL 0 15 (44.1) 15 (29.4) 15 (17.9) 
FL, grade 3b 0 1 (2.9) 1 (2.0) 1 (1.2) 
MCL 0 7 (20.6) 11 (21.6) 11 (13.1) 
Mediastinal large B-cell lymphoma 0 1 (2.9) 1 (2.0) 1 (1.2) 
PTCL 0 4 (11.8) 17 (33.3) 17 (20.2) 
Anaplastic large-cell lymphoma
c
 0 0 3 (17.6) 3 (3.6) 
Angio-immunoblastic TCLc 0 1 (2.9) 4 (23.5) 4 (4.8) 
PTCLc 0 0 2 (11.8) 2 (2.4) 
PTCL, not otherwise specified
c
 0 3 (8.8) 8 (47.1) 8 (9.5) 
Transformed indolent FL 0 6 (17.6) 6 (11.8) 6 (7.1) 
Stage at study entry, n (%)d     
I 1 (3.0) 0 1 (2.0) 2 (2.9) 
II 4 (12.1) 3 (8.8) 5 (9.8) 9 (10.7) 
III 5 (15.2) 7 (20.6) 12 (23.5) 17 (20.2) 
IV 9 (42.4) 24 (70.6) 33 (64.7) 42 (50.0) 
50
51
52
53
54
55
56
57
58
59
60
3 
Data missing for one patient. 
Percentage expressed as a proportion of the total number of patients with FL. 
Percentage expressed as a proportion of the total number of patients with PTCL. 
Data missing for 14 patients with indolent lymphoma. 
CLL – chronic lymphocytic leukemia; DLBCL – diffuse large B-cell lymphoma; FL – follicular lymphoma; MCL – mantle cell lymphoma; MZL – marginal 
zone lymphoma; PTCL – peripheral T-cell lymphoma; SLL – small lymphocytic lymphoma; TCL – T-cell lymphoma. 
50
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53
54
55
56
57
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59
60
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Table 2.  Response evaluation by independent assessment (per protocol set) 
n (%) Indolent  
cohort 
(n=32)
a
 
Aggressive  
cohort, primary 
analysis set 
(n=34) 
Aggressive  
cohort, all 
(n=48)
b
 
Best response    
Complete response 2 (6.3) 0 2 (4.2) 
Unconfirmed complete 
response 
1 (3.1) 4 (11.8) 2 (4.2) 
Partial response 11 (34.4) 6 (17.7) 9 (18.8) 
Stable disease 15 (46.9) 6 (17.7) 11 (22.9) 
Progressive disease 1 (3.1) 10 (29.4) 16 (33.3) 
Not available/not evaluable
c
 2 (6.3) 8 (23.5) 8 (16.7) 
Objective response rate 14 (43.8) 10 (29.4) 13 (27.1) 
Disease control rate
d
 29 (90.6) 16 (47.1) 24 (50.0) 
aOne patient was excluded as they did not have measurable lesion as per Cheson criteria at baseline. 
bThree patients were excluded because: baseline computed tomography or magnetic resonance 
imaging of all suspected disease sites and tumor evaluations were not taken within 28 days before 
starting study treatment (one patient); no measurable lesion was observed (one patient); and no post-
baseline tumor assessment was available and discontinuation was not caused by a drug-related 
toxicity, death, or progression by clinical judgment before disease was re-evaluated (one patient). 
cIncludes patients without post-baseline tumor assessment. 
d
Disease control rate was defined as the proportion of patients with a complete response, an 
unconfirmed complete response, a partial response, or stable disease. 
1 
Table 3.  Summary of TEAEs irrespective of causality (safety analysis set)
a
 
 (%) Indolent cohort 
(n=33) 
Aggressive cohort 
(n=51) 
Total 
(N=84) 
Patients with ≥1 TEAEs 33 (100) 51 (100) 84 (100) 
Worst grade    
1 0 0 0 
2 2 (6.1) 5 (9.8) 7 (8.3) 
3 21 (63.6) 30 (58.8) 51 (60.7) 
4 7 (21.2) 9 (17.6) 16 (19.0) 
5
b
 3 (9.1) 7 (13.7) 10 (11.9) 
Patients with any TEAE leading to permanent discontinuation of 
study drug 
11 (33.3) 10 (19.6) 21 (25.0)c 
Patients with any TEAE leading to dose reduction 4 (12.1) 7 (13.7) 11 (13.1) 
Patients with any TEAE leading to dose interruption 22 (66.7) 28 (54.9) 50 (59.5) 
TEAEs occurring in ≥10% of patients overall
d
 All grades Grade 3 or 4 All grades Grade 3 or 4 All grades Grade 3 or 4 
Hyperglycemia 23 (69.7) 10 (30.3) 27 (52.9) 11 (21.6) 50 (59.5) 21 (25.0) 
Hypertension 23 (69.7) 16 (48.5) 23 (45.1) 18 (35.3) 46 (54.8) 34 (40.5) 
Fatigue 22 (66.7) 4 (12.1) 19 (37.3) 6 (11.8) 41 (48.8) 10 (11.9) 
50
51
52
53
54
55
56
57
58
59
60
2 
Diarrhea 13 (39.4) 1 (3.0) 21 (41.2) 3 (5.9) 34 (40.5) 4 (4.8) 
Decreased neutrophil count 13 (39.4) 11 (33.3) 16 (31.4) 14 (27.5) 29 (34.5) 25 (29.8) 
Nausea 10 (30.3) 0 18 (35.3) 2 (3.9) 28 (33.3) 2 (2.4) 
Anemia 11 (33.3) 5 (15.2) 13 (25.5) 7 (13.7) 24 (28.6) 12 (14.3) 
Oral mucositis 8 (24.2) 1 (3.0) 11 (21.6) 0 19 (22.6) 1 (1.2) 
Lung infection 8 (24.2) 4 (12.1) 9 (17.6) 6 (11.8) 17 (20.2) 10 (11.9) 
Fever 9 (27.3) 1 (3.0) 7 (13.7) 0 16 (19.0) 1 (1.2) 
Decreased platelet count 8 (24.2) 5 (15.2) 7 (13.7) 5 (9.8) 15 (17.9) 10 (11.9) 
Headache 6 (18.2) 0 9 (17.6) 0 15 (17.9) 0 
Urinary tract infection 7 (21.2) 0 7 (13.7) 2 (3.9) 14 (16.7) 2 (2.4) 
Dyspnea 7 (21.2) 1 (3.0) 7 (13.7) 2 (3.9) 14 (16.7) 3 (3.6) 
Constipation 5 (15.2) 0 8 (15.7) 0 13 (15.5) 0 
Skin and subcutaneous disorders - other 9 (27.3) 0 3 (5.9) 0 12 (14.3) 0 
Anorexia 5 (15.2) 0 7 (13.7) 1 (2.0) 12 (14.3) 1 (1.2) 
Vomiting 5 (15.2) 0 6 (11.8) 1 (2.0) 11 (13.1) 1 (1.2) 
Abdominal pain 6 (18.2) 1 (3.0) 4 (7.8) 1 (2.0) 10 (11.9) 2 (2.4) 
Musculoskeletal and connective tissue disorders - other 8 (24.2) 0 2 (3.9) 0 10 (11.9) 0 
50
51
52
53
54
55
56
57
58
59
60
3 
Cough 5 (15.2) 0 5 (9.8) 0 10 (11.9) 0 
Infections and infestations - other 4 (12.1) 2 (6.1) 6 (11.8) 1 (2.0) 10 (11.9) 3 (3.6) 
Bronchial infection 4 (12.1) 0 5 (9.8) 1 (2.0) 9 (10.7) 1 (1.2) 
Upper respiratory infection 5 (15.2) 1 (3.0) 4 (7.8) 0 9 (10.7) 1 (1.2) 
Clinical laboratory       
Increased alanine aminotransferasee,f 9 (28.1) 2 (6.3) 12 (24.0) 1 (2.0) 21 (25.6) 3 (3.7) 
Increased aspartate aminotransferase
e,g
 11 (34.4) 1 (3.1) 10 (20.0) 1 (2.0) 21 (25.6) 2 (2.4) 
Increased alkaline phosphatase 13 (40.6) 0 15 (30.0) 1 (2.0) 28 (34.1) 1 (1.2) 
Adverse events of interest       
Pneumonitis 0 0 3 (5.9) 2 (3.9) 3 (3.6) 2 (2.4) 
October 2015 data set including all patients. 
Deaths are presented for ≤30 days following the last infusion of study drug and include infections and infestations in five patients (meningitis, pneumonia, 
lower respiratory tract infection, pyelonephritis, and septic shock), general disorders in two patients (deterioration in general physical health and multi-organ 
dysfunction syndrome), and acute respiratory failure, circulatory collapse, and progressive disease in one patient each. 
Adverse events leading to permanent discontinuation of study drug included grade 3 fatigue, lung infection, pneumonitis, and maculo-papular rash in 
two patients each (2.4%), and grade 4 lipase increase, serum amylase increase, autoimmune disorder, and meningitis in one patient each (1.2%). 
Common Terminology Criteria for Adverse Events version 4.0. 
One patient each missing from the indolent and aggressive cohorts. 
50
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4 
Grade 1 events were reported in 19 patients (23.2%) overall. 
Grade 1 events were reported in 20 patients (24.4%) overall. 
TEAE – treatment-emergent adverse event. 
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